Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Dec 21;13:1052060. doi: 10.3389/fphar.2022.1052060

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Giudice, Serio, Ferrara, Manzo, Gorrese, Pepe, Bertolini, D’Alto, Verdesca, Langella, Filippelli and Selleri.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Laboratory parameters and prognosticators (A) hemoglobin (Hb) levels (B) platelets count, and (C) absolute neutrophil count variations at baseline and during treatment in azacytidine plus venetoclax (aza-venetoclax cohort) or to azacytidine as single agent (historical cohort) groups are reported (D) differences in Tim-3 expression [reported as fold-change (FC) to healthy controls] based on disease [acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS) vs. MDS with excess of blast of type 1 (MDS-EB 1)] or treatment type [azacytidine + venetoclax vs. azacytidine alone vs. standard chemotherapy (CTX)]. Similarly (E) galectin-9 and (F) CD27 FC variations are displayed based on disease type and during treatment (G) Overall survival (OS) and progression-free survival (PFS) are reported for patients treated with azacytidine plus venetoclax divided by normalized WT1 expression levels and flow cytometric normalized blast count (NBC) values (H) OS of patients with WT1 > cut-off (50 copies in peripheral blood or 250 copies in bone marrow) + NBC >0.5 were compared between aza-venetoclax and historical AML cohort.